<i>PARP9</i> Modulates Sunitinib Resistance in Clear Cell Renal Cell Carcinoma via <i>STAT1</i>/<i>IRF1</i> Signaling Pathway. [PDF]
Luo L +6 more
europepmc +1 more source
A false sense of hypoxia: Pro‑tumorigenic VHL‑HIF2α dysregulation in clear cell renal cell carcinoma (Review). [PDF]
A Rahman NQA +3 more
europepmc +1 more source
Late-Onset Hypertension Is Associated With Improved Clinical Outcomes in Cancer Patients Treated With Sunitinib. [PDF]
Kadowaki H +13 more
europepmc +1 more source
First-line immune checkpoint inhibitor plus anti-angiogenic therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials. [PDF]
Liu Z, Jiang Y, Zhang Z, Liu J.
europepmc +1 more source
RETRACTED: Mohamad et al. Secukinumab and Black Garlic Downregulate OPG/RANK/RANKL Axis and Devitalize Myocardial Interstitial Fibrosis Induced by Sunitinib in Experimental Rats. <i>Life</i> 2023, <i>13</i>, 308. [PDF]
Mohamad HE +7 more
europepmc +1 more source
Nilotinib revisited in GIST: salvage use in patients with severe imatinib toxicity. [PDF]
Falkenhorst J +19 more
europepmc +1 more source
Colonic Recurrence of Clear Cell Renal Cell Carcinoma 13 Years After Nephrectomy: A Case Report. [PDF]
Klarin I.
europepmc +1 more source
Promoter Hypermethylation-Driven NPHS2 Silencing Promotes Immune Escape and Sunitinib Resistance in Clear Cell Renal Cell Carcinoma. [PDF]
Li S, Han Q, Sun X, Yu R.
europepmc +1 more source
First-Line Treatment Strategies in IMDC Favourable-Risk Metastatic Clear Cell Renal Cell Carcinoma. [PDF]
Valdés A +3 more
europepmc +1 more source

